Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered Paper session 1: GI, lower digestive

314O - Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): A randomized phase III study


11 Sep 2022


Proffered Paper session 1: GI, lower digestive


Clinical Research;  Surgical Oncology

Tumour Site

Colon and Rectal Cancer


Alvaro Arjona-Sanchez


Annals of Oncology (2022) 33 (suppl_7): S136-S196. 10.1016/annonc/annonc1048


A. Arjona-Sanchez1, M.T. Cano-Osuna2, A. Gutierrez3, J.J. Segura4, E. Perez5, V. concepcion6, S. Sanchez7, A. Garcia8, I. Prieto9, P. Barrios Sanchez10, J. Torres11, M. Ramirez12, A. Prada13, J. Carrasco14, M. Artiles15, P. Villarejo16, G. Ortega17, E. Boldo18, E. Aranda19, S. Rufian1

Author affiliations

  • 1 Surgical Oncology, Hospital Universitario Reina Sofía, 14004 - Cordoba/ES
  • 2 Oncology, Hospital Universitario Reina Sofía, 14004 - Cordoba/ES
  • 3 Surgical Oncology, UAH - Universidad de Alcalá, 28801 - Alcalá de Henares/ES
  • 4 Surgical Oncology, Hospital Universitario Son Espases, 07120 - Palma de Mallorca/ES
  • 5 Surgical Oncology, Hospital Universitario de Fuenlabrada, 28942 - Fuenlabrada/ES
  • 6 Surgical Oncology, Hospital Universitario Nuestra Senora de Candelaria, 38010 - Santa Cruz de Tenerife/ES
  • 7 Surgical Oncology, Hospital General Ciudad Real, 13005 - Ciudad Real/ES
  • 8 Surgical Oncology, IVO - Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 9 Surgical Oncology, Hospital Universitario La Paz, 28046 - Madrid/ES
  • 10 Surgical Oncology, Hospital de Sant Joan Despi Moisès Broggi, 8970 - Sant Joan Despí/ES
  • 11 Surgical Oncology, Hospital Torrecardenas, 14004 - Almeria/ES
  • 12 Surgical Oncology, Hospital Reina Sofia, 31500 - Murcia/ES
  • 13 Surgical Oncology, Hospital Universitario Badajoz (Hospital Infanta Cristina), 06080 - Badajoz/ES
  • 14 Surgical Oncology, Hospital Universitario Regional de Malaga, 2 - Malaga/ES
  • 15 Surgical Oncology, Hospital Universitario de Gran Canaria Doctor Negrin, 35010 - Las Palmas de Gran Canaria/ES
  • 16 Surgical Oncology, Hospital Universitario Fundacion Jimenez Diaz, 28040 - Madrid/ES
  • 17 Surgical Oncology, MD Anderson Cancer Center Madrid, 28033 - Madrid/ES
  • 18 Surgical Oncology, Hospital Provincial de Castellón, 12002 - Castellón de La Plana/ES
  • 19 Oncology, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) Hospital Universitario Reina Sofía, 14004 - Córdoba/ES


Login to access the resources on OncologyPRO.

Abstract 314O


Peritoneal metastasis in locally advanced colon cancer (T4 stage) is estimated around 25% at 3 years from surgical resection with a poor prognosis. There is controversy about the results using prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) in this group of patients. We led a randomized controlled trial to determine the efficacy and safety of adjuvant HIPEC in patients with locally advanced colon cancer.


We did an open-label, randomized phase III study in 17 hospitals in Spain. Eligible patients were aged 18-75 years and had locally advanced primary colorectal cancer diagnosed preoperatively (cT4NxM0). Patients were randomly assigned (1:1) to surgery or surgery plus HIPEC (mitomycin C 30 mg/m2 during 60 minutes), both followed by systemic adjuvant chemotherapy. Randomisation was done via a web-based system, with stratification by treatment centre and gender. The primary outcome was 3 years loco-regional control rate, defined as the time from treatment to peritoneal disease recurrence or death form any cause, analysed by intention to treat (ITT). DFS and OS were secondary endpoints.


Between November 2015 and January 2021 184 patients were recruited and randomized (89 experimental vs. 95 control). The median of follow-up was 36 (IQR 27-36) months. Demographic, tumour features, surgical management and final pathology reports were similar between both groups. The loco-regional control (LC) was improved in the experimental arm (35,3 ± 0.4 vs. 33.2 ± 0.8 months) with a 3 years LC rate of 97% vs. 87% (p = 0.025). No differences were observed in DFS and OS. The pT4 subgroup showed a clear benefit of LC in the HIPEC arm. No differences in morbidity were observed between groups.


The addition of hyperthermic intraperitoneal chemotherapy with mitomycin C to a complete surgical resection for locally advanced colon cancer improves the loco-regional control rate. This benefit becomes more evident in the subgroup of patients with pT4 colon cancer.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

IMIBIC Maimonides Biomedical research Institute cordoba, Spain. Universitary Hospital Reina Sofia, Cordoba, Spain.


FIBICO (Biomedical Research Foundation, Cordoba) and Spanish Surgeon's Association (AEC).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.